| Zhang, Wei |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression |
|
|
| Recruiting | 2 | 260 | RoW | Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule | Tasly Pharmaceutical Group Co., Ltd | Depression | 04/25 | 04/25 | | |
NCT06093841: Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL |
|
|
| Not yet recruiting | 2 | 46 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma | 08/24 | 02/27 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05577091: Tris-CAR-T Cell Therapy for Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 10 | RoW | Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes., Autologous Tris-CAR-T cell. | Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Tasly Pharmaceutical Group Co., Ltd | Recurrent Glioblastoma | 11/24 | 11/32 | | |
NCT05634473: A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test |
|
|
| Not yet recruiting | N/A | 280 | RoW | Methacholine Chloride | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Asthma | 02/23 | 06/23 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Wang, Ning |
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A |
|
|
| Completed | 3 | 176 | RoW | PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution | Tasly GeneNet Pharmaceuticals Co., Ltd | Charcot-Marie-Tooth Type 1A | 03/24 | 03/24 | | |
| Recruiting | 3 | 248 | RoW | pimavanserin tartrate, placebo | Tasly Pharmaceutical Group Co., Ltd | Parkinson's Disease Psychosis | 06/25 | 01/26 | | |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
| Wang, Xin Shelley |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 240 | RoW | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Suzhou Alphamab Co., Ltd. | Knee Arthroplasty, Total | 12/25 | 04/26 | | |
POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 186 | RoW | Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor) | Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene | Locally Advanced Rectal Cancer | 03/24 | 09/29 | | |
NCT06642545: Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin, RC48, RC148, Albumin-bound Paclitaxone, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 10/26 | 10/27 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT06024915: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets |
|
|
| Not yet recruiting | 1 | 40 | RoW | TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 10/23 | 12/23 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
NCT06344936: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 28 | RoW | HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules | Shandong Suncadia Medicine Co., Ltd. | Chronic Kidney Disease(CKD) | 07/24 | 07/24 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT00505245: New Assessment System in Measuring Symptom Distress in Cancer Patients |
|
|
| Recruiting | N/A | 6500 | US | Interview, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI), Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, National Institutes of Health (NIH) | Caregiver, Health Care Provider, Malignant Neoplasm, Physician | 04/31 | 04/31 | | |
| Guo, Jun |
| Active, not recruiting | 3 | 390 | RoW | CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus | AnewPharma | Renal Cell Cancer Metastatic | 02/21 | 12/21 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
NCT06738251: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma |
|
|
| Not yet recruiting | 3 | 402 | RoW | SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium for Injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Urothelial Carcinoma | 07/26 | 09/27 | | |
NCT05647954: A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver |
|
|
| Not yet recruiting | 3 | 350 | RoW | HX008 + TACE, Temozolomide + TACE, Pembrolizumab | Taizhou Hanzhong biomedical co. LTD | Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms | 12/24 | 06/25 | | |
| Recruiting | 3 | 340 | RoW | OH2, Salvage chemotherapy or best supportive care | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 03/25 | 03/26 | | |
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma |
|
|
| Recruiting | 3 | 452 | RoW | RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin | RemeGen Co., Ltd. | Urothelial Carcinoma, HER2-expressing | 12/26 | 04/28 | | |
NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma |
|
|
| Recruiting | 3 | 165 | RoW | tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin | Shanghai Kechow Pharma, Inc. | Melanoma | 09/27 | 09/27 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
| Active, not recruiting | 2 | 119 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Melanoma | 08/20 | 11/21 | | |
RC48-C009, NCT03809013: A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Completed | 2 | 64 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Urothelial Carcinoma | 03/21 | 06/23 | | |
NCT04200040: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients |
|
|
| Recruiting | 2 | 165 | RoW | OrienX010 injection, Recombinant Human GM-CSF Herpes Simplex Virus Injection, Dacarbazine (DTIC) | OrienGene Biotechnology Ltd. | Melanoma (Skin) | 12/22 | 12/22 | | |
| Completed | 2 | 100 | RoW | HL-085 | Shanghai Kechow Pharma, Inc. | Melanoma | 02/23 | 02/23 | | |
NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | QLF31907 | Qilu Pharmaceutical Co., Ltd. | Melanoma, Urothelial Carcinoma | 10/23 | 07/24 | | |
NCT05135715: A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) |
|
|
| Recruiting | 2 | 50 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Melanoma, Stage II, HER2-positive, Advanced Melanoma | 12/24 | 12/25 | | |
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer |
|
|
| Recruiting | 2 | 115 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Bladder Urothelial Cancer | 12/24 | 06/25 | | |
NCT06227156: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin Injection, DV,RC48 | RemeGen Co., Ltd. | Castration-resistant Prostate Cancer | 12/25 | 06/26 | | |
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 40 | RoW | RC48-ADC, JS001 | RemeGen Co., Ltd. | Muscle Invasive Bladder Carcinoma | 06/24 | 02/25 | | |
NCT05263453: HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation |
|
|
| Recruiting | 2 | 104 | RoW | HL-085, Vemurafenib | Shanghai Kechow Pharma, Inc. | Melanoma | 09/24 | 12/24 | | |
SHR-4602-202, NCT06704828: A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 20 | RoW | SHR-4602 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 04/27 | 04/27 | | |
MIZAR-003, NCT06703398: A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 98 | RoW | GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin | Shanghai Juncell Therapeutics | Melanoma | 07/26 | 12/26 | | |
NCT06797297: A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy |
|
|
| Not yet recruiting | 2 | 180 | RoW | IBI363, Pembrolizumab | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 03/26 | 06/27 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 120 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 06/25 | 07/26 | | |
NCT03676946: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 15 | RoW | ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg | Lee's Pharmaceutical Limited | Urothelial Carcinoma | 02/20 | 06/23 | | |
NCT03973151: Study of HL-085 in NRAS Mutant Advanced Melanoma |
|
|
| Completed | 1/2 | 42 | RoW | HL-085 | Shanghai Kechow Pharma, Inc. | Melanoma | 01/21 | 01/21 | | |
NCT05258266: A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 76 | RoW | ZX-101A | Nanjing Zenshine Pharmaceuticals | Advanced Solid Tumor | 06/23 | 04/24 | | |
NCT06359860: A Study of ST-1898 for Unresectable or Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 64 | RoW | ST-1898 tablets | Beijing Scitech-Mq Pharmaceuticals Limited | Unresectable or Metastatic Melanoma | 09/25 | 09/25 | | |
NCT04616443: OH2 Injection in Combination With HX008 for Melanoma. |
|
|
| Recruiting | 1/2 | 60 | RoW | OH2 injection, HX008 injection | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04618393: A Study of EMB-02 in Participants With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 47 | US, RoW | EMB-02 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumors | 07/23 | 03/24 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/25 | 09/25 | | |
NCT06209580: AMT-253 in Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 96 | RoW | AMT-253 for injection | Multitude Therapeutics Inc. | Malignant Melanoma, Advanced Solid Tumors | 04/25 | 12/25 | | |
| Recruiting | 1/2 | 30 | RoW | OH2 injection, Keytruda, pembrolizumab | Binhui Biopharmaceutical Co., Ltd. | Solid Tumor, Melanoma | 03/25 | 12/25 | | |
NCT06727630: A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 40 | RoW | PRJ1-3024 | Zhuhai Yufan Biotechnologies Co., Ltd | Melanoma | 04/25 | 10/25 | | |
| Recruiting | 1/2 | 80 | RoW | SHR-A2102, SHR-A2102 ; Adebrelimab injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 07/27 | 07/27 | | |
| Recruiting | 1/2 | 84 | RoW | KD6001, Toripalimab, JS001 | Shanghai Kanda Biotechnology Co., Ltd. | Melanoma | 12/24 | 12/25 | | |
NCT05794425: Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders |
|
|
| Recruiting | 1/2 | 100 | RoW | Cyclosporine A, Umbilical cord blood & Umbilical cord derived mesenchymal stem cells | Shandong Qilu Stem Cells Engineering Co., Ltd., Shandong Provincial Third Hospital, Dezhou People's Hospital, Children's Hospital Affiliated to Shandong University, The Second Affiliated Hospital of Shandong First Medical University, Tai'an Central Hospital, Linyi People's Hospital, Linyi Central Hospital, Rizhao People's Hospital, Lanling People's Hospital, Shandong Jining No.1 People's Hospital, The affiliated hospital of Jining medical college, Zibo municipal hospital, Binzhou People's Hospital, The Affiliated Hospital of Binzhou Medical College, Shengli Oilfield Central Hospital, Weihai Municipal Hospital, Weihai Central Hospital, The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine (TCM), Wuwei People's Hospital, Gansu Wuwei Tumour Hospital, The Second Affiliated Hospital of Harbin Medical University, Yuncheng Institute of Hematology, Kaifeng Central Hospital, Zhengzhou Central Hospital, Air Force Hospital of Western War Zone, The First People' s Hospital of Yunnan Province, Zigong No.1 Peoples Hospital, The First People's Hospital of Jingzhou, Jiangxi Province Children's Hospital, Second Affiliated Hospital of Zhengzhou University, Shandong University of Traditional Chinese Medicine, Yantai Ludong Hospital (Shandong Provincial Hospital Group) | Bone Marrow Failure Disorders | 04/25 | 04/26 | | |
| Recruiting | 1/2 | 20 | RoW | GC101 TIL | Shanghai Juncell Therapeutics | Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy, Adverse Drug Event | 04/25 | 07/25 | | |
Triumph-01, NCT05909436: Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors |
|
|
| Recruiting | 1/2 | 107 | RoW | GLS-012, GLS-010 | Guangzhou Gloria Biosciences Co., Ltd. | Solid Tumor | 12/26 | 12/26 | | |
NCT06079112: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer |
|
|
| Recruiting | 1/2 | 100 | RoW | 9MW2821, 9MW2821 injection, Toripalimab, Toripalimab injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/27 | | |
TWP-101-11, NCT04871334: Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 1a/1b | 76 | RoW | TWP-101, Sytalizumab Injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Melanoma, Advanced Urothelial Carcinoma | 10/22 | 12/22 | | |
NCT06049030: A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 1a/1b | 190 | NA | HS-10516 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Renal Cell Carcinoma | 09/24 | 09/25 | | |
NCT04756934: A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 63 | RoW | HX008, LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Melanoma | 08/21 | 08/22 | | |
NCT03932253: MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) |
|
|
| Suspended | 1 | 79 | RoW | FCN-159 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Melanoma | 04/23 | 04/24 | | |
NCT04842630: A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 11 | RoW | SHR-1916 | Jiangsu HengRui Medicine Co., Ltd. | Unspecified Adult Solid Tumor, Protocol Specific | 11/22 | 11/22 | | |
TQB2618-Ib-01, NCT05451407: Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 50 | RoW | TQB2618 injection, Toripalimab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Melanoma | 10/23 | 12/23 | | |
NCT04727164: Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003 and Triprilimab, HBM4003 | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 11/23 | 11/23 | | |
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma |
|
|
| Recruiting | 1 | 88 | RoW | LBL-007, Toripalimab, Axitinib Tablets | Nanjing Leads Biolabs Co.,Ltd | Advanced Melanoma | 07/25 | 12/25 | | |
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 1 | 45 | RoW | B001 injection, Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NMO Spectrum Disorder | 12/25 | 12/25 | | |
NCT06155084: A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients |
|
|
| Recruiting | 1 | 62 | RoW | HP518 - Dose Escalation, Part 1 - Dose Escalation, HP518 -Dose Expansion, Part 2 - Dose Expansion Oral tablet(s) | Hinova Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 09/26 | | |
NCT05393427: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | 06/25 | 06/25 | | |
NCT06220838: Study SC-101 in Subjects with Advanced Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | SC-101 | Tianjin ConjuStar Biologics Co., Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
NCT06321250: A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 80 | RoW | JMKX003948 | Jemincare, Zhejiang Hangyu Pharmaceutical Co., Ltd | Renal Cell Carcinoma Metastatic | 05/26 | 04/27 | | |
NCT05148325: Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 64 | RoW | BAT4706 | Bio-Thera Solutions, Peking University Cancer Hospital & Institute | Advanced Solid Tumor, Melanoma | 12/24 | 12/24 | | |
NCT05773937: A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 12/24 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Recruiting | 1 | 252 | RoW | SHR-A2102 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Or Metastatic Solid Tumor Malignancies | 08/25 | 08/25 | | |
NCT05766527: A Study of KM602 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 38 | RoW | KM602 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor | 12/25 | 12/26 | | |
| Wang, Ming |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
| Li, Bo |
NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 72 | RoW | HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA® | Taizhou Hanzhong biomedical co. LTD | Hepatocellular Carcinoma | 04/22 | 10/22 | | |
| Li, Qiang |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
NCT05638776: Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Diffusion Capacity Defect by REGEND001 Cell Therapy |
|
|
| Active, not recruiting | 2 | 58 | RoW | REGEND001 cell therapy, Placebo | Regend Therapeutics, The First Affiliated Hospital of Guangzhou Medical University, Southwest Hospital, China, Shanghai Zhongshan Hospital, China-Japan Friendship Hospital, Shanghai East Hospital, Regend Therapeutics XLotus (Jiangxi) Co, Ltd., The First Affiliated Hospital of Nanchang University, Xiangya Hospital of Central South University, The First Affiliated Hospital of Soochow University | Chronic Obstructive Pulmonary Disease | 06/25 | 12/25 | | |
| Liu, Qiang |
NCT06049940: Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population |
|
|
| Completed | 3 | 1260 | RoW | Investigational tetanus vaccine, adsorbed, Control tetanus vaccine, adsorbed | Sinovac Life Sciences Co., Ltd. | Tetanus | 10/23 | 03/24 | | |
NCT05159193: Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer |
|
|
| Recruiting | 3 | 372 | RoW | pegylated liposomal doxorubicin (PLD), duomeisu, Doxorubicin Hydrochloride Liposome Injection, cyclophosphamide (C), huanlinxianan, trastuzumab (H), qutuozhudankang, pertuzumab (P), patuozhudankang, docetaxel (T), duoxitasai, carboplatin (Cb), kabo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 10/24 | 01/28 | | |
